Insmed (INSM) Other Non-Current Assets (2011 - 2026)
Insmed (INSM) recorded quarterly Other Non-Current Assets of $99.3 million in Q1 2026, up 1.95% quarter-over-quarter from $97.4 million in Q4 2025, and up 10.6% on a YoY basis from $89.8 million in Q1 2025.
Insmed (INSM) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Insmed's Other Non-Current Assets history runs 16 years deep, the most recent figure standing at $99.3 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 10.6% year-over-year to $99.3 million; the TTM figure through Mar 2026 stood at $99.3 million (up 10.6% YoY), while the FY2025 annual figure was $97.4 million, up 4.45% from the prior year.
- Other Non-Current Assets was $99.3 million for Q1 2026 at Insmed, up from $97.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $99.3 million in Q1 2026 to a low of $57.2 million in Q1 2022.
- Historically, Other Non-Current Assets has averaged $85.6 million across 5 years, with a median of $89.8 million in 2025.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets surged 49.25% in 2022, then retreated 6.21% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $76.1 million in 2022, then gained by 26.9% to $96.6 million in 2023, then slipped by 3.47% to $93.2 million in 2024, then gained by 4.45% to $97.4 million in 2025, then increased by 1.95% to $99.3 million in 2026.
- The last three Other Non-Current Assets figures came in at $99.3 million (Q1 2026), $97.4 million (Q4 2025), and $91.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn | 99.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 99.28 Mn |
| Dec 31, 2025 | 97.38 Mn |
| Sep 30, 2025 | 91.61 Mn |
| Jun 30, 2025 | 88.81 Mn |
| Mar 31, 2025 | 89.76 Mn |
| Dec 31, 2024 | 93.23 Mn |
| Sep 30, 2024 | 96.86 Mn |
| Jun 30, 2024 | 85.83 Mn |
| Mar 31, 2024 | 95.70 Mn |
| Dec 31, 2023 | 96.57 Mn |
| Sep 30, 2023 | 92.49 Mn |
| Jun 30, 2023 | 83.45 Mn |
| Mar 31, 2023 | 81.32 Mn |
| Dec 31, 2022 | 76.10 Mn |
| Sep 30, 2022 | 63.71 Mn |
| Jun 30, 2022 | 66.30 Mn |
| Mar 31, 2022 | 57.20 Mn |
| Dec 31, 2021 | 50.99 Mn |
| Sep 30, 2021 | 47.60 Mn |
| Jun 30, 2021 | 49.24 Mn |